Amicus Therapeutics, Inc. - Laporan Laba Rugi (TTM)

Amicus Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03152W1099

Laporan Laba Rugi (TTM)

Laporan Laba Rugi Amicus Therapeutics, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 246 261 267 282 294 306 318 321 323 329 337 351 372 399 423 456 494 528 543 571
Change (%) 6.22 2.25 5.65 4.30 3.94 4.03 1.04 0.67 1.84 2.29 4.09 6.22 7.25 6.04 7.60 8.34 7.01 2.81 5.16
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 29 31 31 33 36 34 36 35 37 39 38 39 35 37 44 46 49 53 51 55
Change (%) 8.65 -0.04 5.49 10.07 -4.35 3.03 -0.52 4.93 4.14 -1.66 2.42 -8.98 5.48 17.75 4.88 7.23 7.10 -3.53 7.75
% of Revenue 11.63 11.90 11.63 11.62 12.26 11.28 11.17 11.00 11.47 11.72 11.27 11.09 9.50 9.35 10.38 10.12 10.01 10.02 9.40 9.63
Gross Operating Profit 217 230 236 249 258 271 282 286 286 291 299 312 337 362 380 410 444 475 492 516
Change (%) 5.90 2.56 5.67 3.54 5.10 4.16 1.24 0.14 1.54 2.82 4.30 8.12 7.43 4.84 7.91 8.47 7.00 3.52 4.89
% of Revenue 88.37 88.10 88.37 88.38 87.74 88.72 88.83 89.00 88.53 88.28 88.73 88.91 90.50 90.65 89.62 89.88 89.99 89.98 90.60 90.37
SG&A 156 156 163 171 179 193 204 215 216 213 229 241 259 275 289 297 307 323 327 338
Change (%) 0.25 4.16 4.68 4.84 7.78 5.91 5.44 0.54 -1.54 7.44 5.26 7.63 6.16 5.11 2.82 3.18 5.35 1.17 3.35
% of Revenue 63.52 59.95 61.07 60.51 60.83 63.08 64.22 67.01 66.93 64.71 67.96 68.73 69.64 68.93 68.32 65.29 62.18 61.21 60.24 59.20
R&D 321 308 283 277 266 272 289 305 298 277 237 193 181 152 139 129 114 109 109 145
Change (%) -3.93 -8.11 -2.33 -4.00 2.37 6.40 5.29 -2.09 -7.28 -14.46 -18.24 -6.34 -15.92 -8.64 -7.52 -11.30 -4.24 -0.45 33.22
% of Revenue 130.72 118.23 106.25 98.23 90.41 89.05 91.07 94.90 92.30 84.04 70.27 55.19 48.67 38.16 32.87 28.25 23.13 20.70 20.04 25.39
OpEx 513 505 486 488 488 505 535 561 557 534 509 479 483 473 481 481 479 494 495 546
Change (%) -1.70 -3.70 0.46 -0.10 3.61 5.86 4.86 -0.66 -4.26 -4.68 -5.77 0.74 -2.08 1.78 -0.04 -0.38 3.12 0.23 10.25
% of Revenue 209.06 193.47 182.21 173.27 165.96 165.44 168.35 174.71 172.41 162.09 151.04 136.74 129.69 118.40 113.64 105.58 97.08 93.55 91.20 95.61
Operating Income -268 -244 -219 -206 -194 -200 -217 -240 -234 -204 -172 -129 -111 -73 -58 -25 14 34 48 25
Change (%) -8.96 -10.06 -5.84 -6.11 3.12 8.67 10.44 -2.43 -12.67 -15.91 -25.08 -14.17 -33.52 -21.37 -55.99 -156.63 136.54 40.29 -47.58
% of Revenue -109.06 -93.47 -82.21 -73.27 -65.96 -65.44 -68.35 -74.71 -72.41 -62.09 -51.04 -36.74 -29.69 -18.40 -13.64 -5.58 2.92 6.45 8.80 4.39
Interest Expense -18 -22 -27 -31 -33 -32 -33 -33 -34 -37 -41 -45 -48 -50 -51 -51 -50 -50 -49 -48
Change (%) 25.17 19.01 16.92 4.43 -0.35 0.48 0.33 4.45 8.57 9.96 10.38 7.47 3.58 1.18 0.04 -0.58 -1.72 -1.98 -1.95
% of Revenue -7.29 -8.60 -10.00 -11.07 -11.09 -10.63 -10.27 -10.19 -10.57 -11.27 -12.12 -12.85 -13.00 -12.56 -11.98 -11.14 -10.22 -9.39 -8.95 -8.35
Net Income -295 -277 -254 -252 -239 -250 -270 -281 -264 -237 -204 -185 -174 -152 -147 -120 -105 -56 -29 -38
Change (%) -6.21 -8.41 -0.50 -5.44 4.98 7.82 4.05 -6.05 -10.38 -13.67 -9.27 -6.32 -12.69 -2.98 -18.72 -12.42 -46.41 -47.65 29.70
% of Revenue -120.18 -106.12 -95.05 -89.52 -81.17 -81.98 -84.97 -87.50 -81.65 -71.85 -60.64 -52.86 -46.62 -37.96 -34.73 -26.23 -21.21 -10.62 -5.41 -6.67

Source: Capital IQ

Other Listings
GB:0HF9
DE:AM6 € 6.70
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista